{"id":22693,"date":"2026-02-02T12:06:20","date_gmt":"2026-02-02T03:06:20","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4528-20260202-01_wp_financial_summary\/"},"modified":"2026-02-02T12:06:20","modified_gmt":"2026-02-02T03:06:20","slug":"4528-20260202-01_wp_financial_summary","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4528\/ir\/4528-20260202-01_wp_financial_summary\/","title":{"rendered":"FY2026 Q3 Financial Summary [IFRS] (Consolidated)"},"content":{"rendered":"<p>For FY2026 Q3, revenue was 397.0 billion yen (6.0% YoY increase), operating income was 88.2 billion yen (24.8% YoY increase), and quarterly profit was 68.9 billion yen (21.8% YoY increase).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4528","jir_company_name":"Ono Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4528-20260202-01.pdf","jir_short_summary":"For FY2026 Q3, revenue was 397.0 billion yen (6.0% YoY increase), operating income was 88.2 billion yen (24.8% YoY increase), and quarterly profit was 68.9 billion yen (21.8% YoY increase).","jir_summary":"### Performance Overview\nFor FY2026 Q3 consolidated results, revenue was 397.0 billion yen (6.0% YoY increase), operating income was 88.2 billion yen (24.8% YoY increase), profit before income taxes for the quarter was 89.4 billion yen (24.1% YoY increase), and quarterly profit was 68.9 billion yen (21.8% YoY increase). On a core basis, revenue was 397.0 billion yen (6.0% increase), core operating income was 116.3 billion yen (19.1% increase), and core quarterly profit was 89.9 billion yen (17.6% increase), achieving profit growth. Key products contributing to growth included the diabetes, chronic heart failure, and chronic kidney disease treatment 'Forxiga Tablets,' which recorded revenue of 72.7 billion yen, a 5.7% increase year-on-year.\n\n### Financial Position and Cash Flow Status\nTotal assets amounted to 1.0844 trillion yen, an increase of 20.4 billion yen from the previous fiscal year-end, and equity attributable to owners of the parent also rose by 57.2 billion yen to 839.7 billion yen. Cash and cash equivalents at the end of the period were 188.3 billion yen, up compared to the same period last year. Cash flow from operating activities was an inflow of 86.6 billion yen, outflows from investing activities were 44.0 billion yen, and outflows from financing activities were 59.8 billion yen.\n\n### Outlook\nThere is no change to the full-year earnings guidance announced on October 30, 2025. Full-year revenue is projected at 490.0 billion yen (0.6% YoY increase), operating income at 85.0 billion yen (42.3% YoY increase), and net income at 67.0 billion yen (33.6% YoY increase).","jir_financial_highlights":"Revenue: 397.0 billion yen (6.0% YoY increase)\nOperating Income: 88.2 billion yen (24.8% YoY increase)\nProfit before Income Taxes for the Quarter: 89.4 billion yen (24.1% YoY increase)\nQuarterly Profit (Net Income Attributable to Owners of Parent): 68.9 billion yen (21.8% YoY increase)\nBasic Earnings per Share for the Quarter: 146.75 yen (YoY increase (unspecified))\nTotal Assets: 1.0844 trillion yen (20.4 billion yen increase from previous fiscal year-end)\nEquity Attributable to Owners of Parent: 839.7 billion yen (57.2 billion yen increase from previous fiscal year-end)\nCash and Cash Equivalents at End of Period: 188.3 billion yen (Increased YoY)","jir_category":"","jir_hashtags":"#OnoPharmaceuticalCoLtd, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Revenue: 397.0 billion yen (6.0% YoY increase)\nOperating Income: 88.2 billion yen (24.8% YoY increase)\nQuarterly Profit (Net Income Attributable to Owners of Parent): 68.9 billion yen (21.8% YoY increase)","jir_meta_title":"Ono Pharmaceutical FY2026 Q3 Financial Results: 397.0 Billion Yen Revenue, 6.0% Increase","jir_meta_description":"Ono Pharmaceutical Co., Ltd.'s FY2026 Q3 Financial Summary. Revenue reached 397.0 billion yen (6.0% YoY increase), operating income 88.2 billion yen (24.8% YoY increase), and quarterly profit 68.9 billion yen (21.8% YoY increase), achieving revenue and profit growth.","jir_og_title":"Ono Pharmaceutical FY2026 Q3 Financial Results Announcement","jir_og_description":"Achieved revenue of 397.0 billion yen, operating income of 88.2 billion yen, and quarterly profit of 68.9 billion yen, showing YoY increases in revenue and profit.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q3 Cumulative\\\",\\\"FY2026 Q3 Cumulative\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[374562,397036],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q3 Cumulative\\\",\\\"FY2026 Q3 Cumulative\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[70754,88292],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"quarter_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Quarterly Profit Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q3 Cumulative\\\",\\\"FY2026 Q3 Cumulative\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly Profit (Net Income Attributable to Owners of Parent)\\\",\\\"data\\\":[56592,68949],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"core_operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Core Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q3 Cumulative\\\",\\\"FY2026 Q3 Cumulative\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Income\\\",\\\"data\\\":[97654,116298],\\\"backgroundColor\\\":\\\"#76b7b2\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"cash_flow_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Cash Flow from Operating Activities (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q3 Cumulative\\\",\\\"FY2026 Q3 Cumulative\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Cash Flow from Operating Activities\\\",\\\"data\\\":[43463,86639],\\\"backgroundColor\\\":\\\"#59a14f\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":7530,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-22693","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FY2026 Q3 Financial Summary [IFRS] (Consolidated) - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4528\/ir\/4528-20260202-01_wp_financial_summary\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4528\/ir\/4528-20260202-01_wp_financial_summary\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4528\/ir\/4528-20260202-01_wp_financial_summary\/\",\"name\":\"FY2026 Q3 Financial Summary [IFRS] (Consolidated) - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-02-02T03:06:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4528\/ir\/4528-20260202-01_wp_financial_summary\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4528\/ir\/4528-20260202-01_wp_financial_summary\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4528\/ir\/4528-20260202-01_wp_financial_summary\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FY2026 Q3 Financial Summary [IFRS] (Consolidated)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FY2026 Q3 Financial Summary [IFRS] (Consolidated) - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4528\/ir\/4528-20260202-01_wp_financial_summary\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4528\/ir\/4528-20260202-01_wp_financial_summary\/","url":"https:\/\/japanir.jp\/en\/company\/company-4528\/ir\/4528-20260202-01_wp_financial_summary\/","name":"FY2026 Q3 Financial Summary [IFRS] (Consolidated) - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-02-02T03:06:20+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4528\/ir\/4528-20260202-01_wp_financial_summary\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4528\/ir\/4528-20260202-01_wp_financial_summary\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4528\/ir\/4528-20260202-01_wp_financial_summary\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"FY2026 Q3 Financial Summary [IFRS] (Consolidated)"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"7530","title":"ONO PHARMACEUTICAL CO","ticker":"4528"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/22693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=22693"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/22693\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=22693"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=22693"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=22693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}